As per the MoU, areas of research collaboration would include genetic diseases that impact infant and neonatal mortality; new diagnostics and devices for infectious disease and environmental surveillance; development of cost-effective processes for drug, vaccines, biologics, and diagnostics manufacturing; novel microbiome-directed foods; socio-economic impact of science and technological tools; and other areas of health and development.